




DGlycemic profile in infants who have undergone the
arterial switch operation: Hyperglycemia is not
associated with adverse events
Joseph W. Rossano, MD,a Michael D. Taylor, MD, PhD,a E. O'Brian Smith, PhD,a Charles D. Fraser, Jr, MD,b
E. Dean McKenzie, MD,b Jack F. Price, MD,a Heather A. Dickerson, MD,a David P. Nelson, MD, PhD,a and
Antonio R. Mott, MDaObjective: Tight glycemic control improves outcomes in critically ill adults. There are
limited data regarding the effect of glycemic profiles in infants after cardiac opera-
tions. The aim of this study was to evaluate the association of hyperglycemia and
hypoglycemia on adverse events in infants undergoing the arterial switch operation.
Methods: From 2000 through 2005, 93 infants underwent the arterial switch operation
(mean age, 2.5 6 5.9 weeks; mean weight, 3.4 6 0.8 kg). All serum glucose values
during the first 24 postoperative hours were documented. The effect of time spent in
specific glycemic bands on adverse events was determined.
Results: Twenty-three (25%; group 1) infants spent more than 50% of the time with
glucose values between 80 and 110 mg/dL, and 13 (14%; group 2) spent more than
50% of the time with glucose values of greater than 200 mg/dL. A total of 71 adverse
events was documented in 45 (48%) of 93 infants. Group 1 infants were more likely to
have any adverse event (P5 .001) and renal insufficiency (P, .001). Group 2 infants
were not more likely to have adverse events. When controlling for preoperative and
operative factors, being in group 1 was an independent predictor of postoperative
adverse events (P 5 .004).
Conclusion:Hyperglycemia does not appear to be detrimental in postoperative infants
with congenital heart disease. Infants who spent the majority of the time with glucose
values between 80 and 110 mg/dL were at increased risk for adverse events. The ideal
glycemic profile in the postoperative cardiac infant has yet to be defined.
S
erum hyperglycemia has been associated with increased morbidity and mortal-
ity in many pathophysiologic states in critically ill adults and children, includ-
ing sepsis,1 myocardial infarction,2,3 and stroke.4 Adults undergoing cardiac
operations also have increased morbidity with intraoperative hyperglycemia.5,6 Addi-
tionally, tight glycemic control with intensive insulin therapy in certain populations of
adult patients, including patients after cardiac operations, significantly improves mor-
bidity and mortality.7 Importantly, hyperglycemia has not been demonstrated to be
a risk factor in other critically ill populations, including patients in general medical
and surgical intensive care units.8,9 Additionally, it is unclear whether short-term hy-
perglycemia in children is significantly detrimental.10 Infants are more reliant on glu-
cose for energy use and have a decreased ability to use alternative energy substrates,
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DAbbreviations and Acronyms
AE 5 adverse event
APC 5 activated protein C
ASO 5 arterial switch operation
CVICU 5 cardiovascular intensive care unit
LOS 5 length of stay
SGV 5 serum glucose value
such as fatty acids.11 Moreover, aggressive treatment of hy-
perglycemia results in more episodes of hypoglycemia,12
which can be particularly detrimental to the neonatal myocar-
dium and central nervous system.13-15
There are very limited data regarding the glycemic profile
of infants after cardiac operations. Furthermore, whether hy-
perglycemia or hypoglycemia is associated with increased
adverse events (AEs) has not clearly been elucidated. There-
fore the purpose of our study was to define the glycemic pro-
file of infants undergoing the arterial switch operation (ASO)
and to evaluate the association of hyperglycemia and hypo-
glycemia with AEs.
Materials and Methods
From January 1, 2000, through October 31, 2005, 93 infants under-
went the ASO at Texas Children’s Hospital, and their medical re-
cords were reviewed. The mean gestational age at birth was 38.7
6 1.8 weeks, and the mean age at the time of the operation was
2.5 6 5.9 weeks. There was 1 (1%) operative mortality. Five pa-
tients underwent delayed sternal closure. Baseline cohort character-
istics are shown in Table 1. The cardiac anatomic diagnoses were
dextro-transposition of the great arteries with ventricular septal de-
fect (n 5 55; 59%) and intact ventricular septum (n 5 31; 33%).
There were 7 (8%) patients with double-outlet right ventricles
with subpulmonic ventricular septal defects (Taussig–Bing anom-
aly). Most patients underwent a balloon atrial septostomy (82%)
and were weaned from prostaglandin infusions (51%) before their
operations. The operative profile is shown in Table 2.
Baseline demographic and medical data were collected, includ-
ing gestational age, weight, cardiac diagnosis, coronary artery anat-
omy as classified by Yacoub and Radley–Smith,16 and preoperative
condition. Operative data collected included the cardiopulmonary
bypass time, the aortic crossclamp time, the use of phenoxybenz-
amine, and the use of corticosteroids. The techniques of anesthesia,
cardiopulmonary bypass, and surgical intervention were standard-
ized in all patients and have been described previously.17 Steroids
during cardiopulmonary bypass were administered at the discretion
of the attending surgeon. Postoperative maintenance fluids consisted
of half-normal saline with 10% dextrose infusing at 1 mL $ kg21 $
h21. A comprehensive review of postoperative morbidities was per-
formed. It was unit policy not to administer insulin to treat hypergly-
cemia.
All serum glucose values (SGVs) for the first 24 hours postoper-
atively were collected. SGVs were obtained every 4 hours postoper-
atively, with additional values obtained at the discretion of the
attending cardiac intensivist. The glycemic profile was divided
into 6 bands: less than 80 mg/dL, 80 to 110 mg/dL, 111 to 150740 The Journal of Thoracic and Cardiovascular Surgery c Apmg/dL, 151 to 199 mg/dL, 200 to 250 mg/dL, and greater than
250 mg/dL. Given that patients had a variety of SGVs recorded in
several bands over this time period, the percentage of time spent
in each glycemic band was calculated similarly to the technique de-
scribed by Finney and colleagues.18 Because there might bemultiple
SGV measurements made when values deviate significantly from
normal, recording the absolute number of SGVs in a given glycemic
band might overestimate the time spent with very high or very low
SGVs. Thus time weighting was used with linear interpolation by
assuming a linear trend between 2 SGVs. This permitted the percent-
age of time spent in each glycemic band to be calculated.
For further analysis, patients were placed into groups based on
the percentage of time spent in certain glycemic bands. Group 1 pa-
tients spent the majority of time with SGVs between 80 and 110 mg/
dL. Group 2 patients spent the majority of time with SGVs greater
than 200 mg/dL.
Statistical analysis was performed on SPSS version 12.0 soft-
ware (Chicago, Ill). Baseline data are presented as percentages or
means with standard deviations. Glucose values were compared at
specific intervals postoperatively with a paired t test. The Student
TABLE 1. Preoperative characteristics (n 5 93)
Demographic data
Female sex, n (%) 33 (35)
Gestational age, wk 38.7 6 1.8
Age at operation, wk 2.5 6 5.9
Birth weight, kg 2.9 6 1.2
Weight at operation, kg 3.4 6 0.8
Anatomic descriptors
D-TGA with IVS, n (%) 31 (33)
D-TGA with VSD, n (%) 55 (59)
Taussig–Bing anomaly, n (%) 7 (8)
Yacoub type A coronary arteries, n (%) 60 (65)
Yacoub type D coronary arteries, n (%) 22 (24)
Single coronary artery, n (%) 8 (9)
Intubated preoperatively, n (%) 26 (28)
Preoperative interventions
Balloon atrial septostomy, n (%) 76 (82)




D-TGA, Dextro-transposition of the great arteries; IVS, intact ventricular
septum; VSD, ventricular septal defect.
TABLE 2. Operative course
Cardiopulmonary bypass time, min 242.5 6 54.3
Aortic crossclamp time, min 139.1 6 41.8
Circulatory arrest, n (%) 35 (38)
Circulatory arrest time, min* 17.7 6 17.3
Regional low-flow perfusion, n (%) 11 (12)
Medications administered during
cardiopulmonary bypass
Steroids, n (%) 70 (75)
Phenoxybenzamine, n (%) 74 (80)
*Only for patients requiring circulatory arrest.ril 2008
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Dt test was used to compare AE (yes/no) groups with respect to the
percentage of time in each SGV band. Two-by-two contingency ta-
bles analysis was used to assess the effect of binary variables on the
development of AEs, with results being expressed as odds ratios
with 95% confidence intervals. Logistic regression analysis was
used to estimate the increase in the odds of development of an AE
for continuous variables.
For continuous variables, such as postoperative and cardiovascu-
lar intensive care unit (CVICU) length of stay (LOS), group status
(ie, group 1 and group 2) was compared with respect to the median
by using the Mann–WhitneyU test. Multiple logistic regression was
used to determine whether group status was independently associ-
ated with the development of an AE.
The study was approved by the Institutional Review Board of
Texas Children’s Hospital and Baylor College of Medicine. Individ-
ual consent was waived.
Results
Resource Use and AEs
The median CVICU LOS was 6 days (25th–75th percentile,
5–7 days), and the median postoperative LOS was 11 days
(25th–75th percentile, 9–14 days). There were 71 AEs (non-
cardiac, n 5 57; cardiac, n 5 14) that occurred in 45 (48%)
of 93 patients. A list of common AEs is shown in Table 3.
Common AEs included infection (bloodstream, urinary, or
respiratory tracheal: n 5 17), renal insufficiency (serum cre-
atinine increase.0.5 mg/dL from baseline: n5 11), cardiac
arrhythmia (n5 8), and intracaval thrombus, atrial thrombus,
or both (n 5 7).
Preoperative and Postoperative Serum Glycemic
Profile
The mean SGV before the ASO was 916 19 mg/dL. Only 1
patient had an SGV of greater than 150 mg/dL. There were
1037 SGVs (11.2 6 3.1 SGVs per patient) documented in
the first 24 postoperative hours. Figure 1 demonstrates the
glucose levels for the overall cohort at specific time intervals
postoperatively. Immediately postoperatively, SGVs were
increased, with a mean of 201 6 82 mg/dL. The SGVs
TABLE 3. Summary of adverse events






Intravascular/intracardiac thrombus 7 (8)
Seizure/stroke 4 (4)
Pleural effusion (requiring treatment) 2 (2)
Cardiac
Postoperative arrhythmia 8 (9)
Ventricular dysfunction ($moderate) 2 (2)
Cardiac arrest 2 (2)
Pericardial effusion (requiring treatment) 1 (1)
Pulmonary hypertensive crisis 1 (1)The Journal of Thordecreased significantly at each 6-hour interval, with most
patients having normal glucose levels by 24 hours postoper-
atively (mean SGV, 1086 38 mg/dL). Figure 2 demonstrates
the overall percentage of time spent in each glycemic band
and the percentage of time spent in each glycemic band in pa-
tients who had and did not have an AE.
Analysis of Serum Glycemic Profile and AEs
Overall, patients spent the least percentage of time with
SGVs of less than 80 mg/dL (mean, 3.0% 6 6.7%) and the
most percentage of time with SGVs between 111 and 150
mg/dL (mean, 30.6% 6 22.4%). AEs were associated with
having spent more time with SGVs of less than 80 mg/dL
(mean, 4.8% 6 8.6% vs 1.4% 6 3.6% in those without an
AE; P 5 0.01), more time with SGVs between 80 and 110
mg/dL (mean, 36.4% 6 32.2% vs 19.2% 6 20.9% in those
without an AE; P 5 .03), and less time with SGVs between
111 and 150 mg/dL (mean, 25.1% 6 20.6% vs 35.7% 6
23.1% in those without an AE; P 5 .03).
The data were also analyzed according to the percentage
of time in the first 24 hours spent in specific glycemic bands:
group 1 patients (n5 23), greater than 50% time with SGVs
between 80 and 110 mg/dL; group 2 patients (n 5 13),
greater than 50% of time with SGVs of greater than 200
mg/dL). Baseline and operative characteristics between
group 1 and group 2 patients are shown in Table 4.
When compared with the remainder of the cohort, patients
in group 1 were more likely to have an all-cause AE
Figure 1. Postoperative glucose values. The horizontal lines in the
box denote the 25th, 50th, and 75th percentile values. The error
bars denote the 5th and 95th percentile values. The 2 symbols be-
low the 5th percentile error bar denote the 0th and 1st percentile
values. The 2 symbols above the 95th percentile error bar denote
the 99th and 100th percentiles. The square symbol in the box
denotes the mean of the column of data.acic and Cardiovascular Surgery c Volume 135, Number 4 741
Surgery for Congenital Heart Disease Rossano et al
CH
DFigure 2. Percentage time spent in spe-
cific glycemic bands. The horizontal
lines in the box denote the 25th, 50th,
and 75th percentile values. The error
bars denote the 5th and 95th percentile
values. The 2 symbols below the 5th
percentile error bar denote the 0th and
1st percentile values. The 2 symbols
above the 95th percentile error bar de-
note the 99th and 100th percentiles.
The square symbol in the box denotes
the mean of the column of data.(P 5 .001), renal insufficiency (P , .001), or an episode of
hypoglycemia (SGV,80 mg/dL, P5 .008; Table 5). Group
1 patients were also at increased risk of having an AE when
compared with group 2 patients (P 5 .03). Common AEs in
group 1 patients included renal insufficiency (n 5 8, 35%),
infection (n 5 5, 22%), and cardiac arrest (n 5 2, 9%).
AEs in group 2 patients included supraventricular tachycar-
dia (n5 3, 23%), infection (n5 1, 8%), and pulmonary hem-
orrhage (n 5 1, 8%). Group 2 patients were not at increased
risk for having an AE compared with the rest of the cohort.
Group status designation was not associated with duration
of mechanical ventilation for more than 48 hours, duration
of inotropic support for more than 48 hours, or CVICU
LOS beyond 72 hours. Additionally, group status designation
was not associated with total duration of mechanical ventila-
tion, inotropic support, CVICU LOS, or postoperative LOS.
By using multivariable analysis and controlling for preop-
erative factors (gestational age, birth weight, age at ASO, pre-
operative serum creatinine value, preoperative glucose value,
preoperative balloon atrial septostomy, preoperative ino-
tropes, anatomic descriptors [cardiac diagnosis and coronary
artery anatomy], intraoperative course [cardiopulmonary by-
pass and aortic crossclamp times], steroid administration dur-
ing cardiopulmonary bypass, and phenoxybenzamine
administration) and postoperative hypoglycemia, being a pa-
tient in group 1 was determined to be independently associ-
ated with an AE (adjusted odds ratio, 13.7; 95% confidence
interval, 2.3–83.0; P 5 .004).742 The Journal of Thoracic and Cardiovascular Surgery c ApDiscussion
We have described in detail the range of SGVs encountered
in infants after the ASO. Only 23% of patients spent the ma-
jority of time with tight glucose control (80–110 mg/dL), as
defined by prior studies from adult intensive care patients.7
Importantly and in contrast to adult patients, the patients in
our study who spent the majority of time with tight glucose
control had an increase in the number of AEs. This risk for
morbidity was also independent of other known risk factors,
including gestational age, birth weight, cardiopulmonary
bypass time, and preoperative condition.
Additionally, patients who spent the majority of time with
the highest SGVs (.200 mg/dL) were not at increased risk
for AEs. The reason for this is not entirely clear. One poten-
tial explanation is that hyperglycemia is part of the normal
response to the stress of cardiac operations,19 which is
mediated in part by increased cortisol, inflammatory cyto-
kines, catecholamine values, and insulin resistance.20 Neo-
nates not exhibiting hyperglycemia after cardiac operations
might have an impaired ability to mount an appropriate stress
response, thereby placing these infants at increased risk for
morbidity.Whether lack of a hyperglycemic response is asso-
ciated with an impaired adrenal axis or cortisol insufficiency
was not addressed in this study. However, this would be an
important avenue of future inquiry and is a focus of investi-
gation at our institution.
This study is in contrast to the other pediatric study that
has evaluated hyperglycemia as a risk factor for AEs inril 2008
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DTABLE 4. Baseline and operative characteristics by group designation
Factor Group 1 (n 5 23) Group 2 (n 5 13) P value
Demographic data
Gestational age, wk 38.7 6 1.6 37.9 6 1.4 .19
Age at operation, wk 3.6 6 8.4 1.5 6 1.2 .38
Birth weight, kg 2.8 6 1.6 2.9 6 0.9 .90
Weight at operation, kg 3.8 6 1.3 3.2 6 0.3 .03
Anatomic descriptors
D-TGA with IVS, n (%) 12 (52) 5(38) .50
D-TGA with VSD, n (%) 7 (30) 7 (53) .29
Taussig–Bing anomaly, n (%) 4 (17) 1(8) .64
Yacoub type A coronary arteries, n (%) 17 (74) 8 (62) .48
Yacoub type D coronary arteries, n (%) 3 (13) 2 (15) 1.0
Single coronary artery, n (%) 3 (13) 2 (15) 1.0
Preoperative interventions
Intubated preoperatively, n (%) 9 (39) 3 (23) .47
Balloon atrial septostomy, n (%) 17 (74) 10 (77) 1.00
Inotropes, n (%) 7 (30) 0 (0) .04
Prostaglandin discontinued before ASO, n (%) 10 (43) 9 (69) .18
Operative course
Cardiopulmonary bypass time, min 246.9 6 63.0 269.1 6 71.1 .34
Aortic crossclamp time, min 148.0 6 50.8 157.4 6 57.1 .61
Circulatory arrest, n (%) 10 (43) 8 (62) .49
Circulatory arrest time, min* 18.1 6 16.1 9.5 6 5.2 .17
Regional low-flow perfusion, n (%) 6 (26) 2 (15) .68
Steroids, n (%) 15 (65) 10 (77) .43
Phenoxybenzamine, n (%) 19 (83) 11 (85) 1.00
D-TGA, Dextro-transposition of the great arteries; IVS, intact ventricular septum; VSD, ventricular septal defect; ASO, arterial switch operation. *Only for
patients who required circulatory arrest.postoperative cardiac patients. In the study by Yates and
associates,21 postoperative hyperglycemia was found to be
associated with increased AEs in an older patient population
undergoing a variety of cardiac operations. This study only
looked at the maximum SGV per day in the postoperative pe-
riod. As is evidenced by Figure 1 of our study, the SGVs are
highly variable over the first 24 hours postoperatively, and
evaluating only one point in time will not likely accurately
reflect the true physiologic state.
There were several other important differences between
our study and the study by Yates and associates.21 Almost
the entire cohort in our study had normal or only mildly in-
creased SGVs 24 hours after their operations, which is in con-
tradistinction to the several days of hyperglycemia noted by
Yates and associates. Additionally, the mortality rate in our
study was 1% compared with the 11% reported by Yates
and associates. Also, our study only included infants, who
might be more susceptible to AEs caused by hypoglycemia.
These differences in the patient population between the stud-
ies might help in part to explain the different findings.
These findings are similar to those of de Ferranti and co-
workers,10 who noted that short-term hyperglycemia did
not predict AEs but periods of hypoglycemia during periods
of stress were disadvantageous. In their study intraoperative
hyperglycemia was not associated with long-term neurodeve-The Journal of Tholopmental outcome but did predict a more rapid normaliza-
tion of the electroencephalogram. Short periods of
hypoglycemia intraoperatively, however, were associated
with more electroencephalographic seizures.
There are several limitations to our study. It is a retrospec-
tive study from a single center, and the findings might not be
applicable to other centers and other populations. Additionally,
SGVs were not controlled with insulin, which might have af-
fected the development of AEs. Insulin has been associated
with an anti-inflammatory effect22 and has been demonstrated
to maintain hepatic mitochondrial ultrastructure,23 which could
be beneficial in critically ill patients. However, in the study by
Finney and colleagues,18 the primary benefit of insulin therapy
was glycemic control and not a beneficial effect from insulin
administration. Increased insulin administration in the same
study was actually associated with increased mortality.
Which critically ill pediatric patients would potentially
benefit from insulin therapy to achieve tight glucose control?
This is an important and still unanswered question. This is
a crucial point because there might be a tendency to adopt
therapies used successfully in adult patients to children be-
fore the safety and efficacy of the therapy has been estab-
lished. This issue is highlighted by the recent pediatric
activated protein C (APC) trial. The trial, which evaluated
the use of APC in patients with sepsis, was haltedracic and Cardiovascular Surgery c Volume 135, Number 4 743
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Dprematurely by the US Food and Drug Administration and
Eli Lilly after the external data-monitoring committee noted
a lack of effectiveness of APC and an increase in the number
of central nervous system hemorrhages in patients adminis-
tered APC.24
In our study patients with the lowest glucose levels had
more AEs, whereas those who spent the most time with
mild hyperglycemia (SGV, 111–150 mg/dL) fared better. It
TABLE 5. Factors associated with adverse events
Factor Odds ratio 95% CI P value
All-cause adverse events
Group 1 5.7 1.9–17.3 .001
Group 2 0.6 0.2–2.1 .55
Birth weight, kg 1.2 0.9–1.7 .31
Gestational age, wk 0.9 0.7–1.2 .56
Age at operation, wk 1.0 0.9–1.1 .38
PGE at time of operation 1.5 0.65–3.3 .36
Preoperative inotropes 2.9 1.0–8.0 .04
Single coronary artery 1.9 0.4–8.4 .48
Steroids on CPB 0.5 0.2–1.5 .22
Phenoxybenzamine 0.8 0.3–2.2 .60
CPB time, min 1.0 0.9–1.1 .09
Aortic crossclamp time, min 1.0 0.9–1.0 .17
Circulatory arrest time, min* 1.1 0.9–1.1 .08
Renal insufficiency
Group 1 11.9 2.8–50.3 ,.001
Group 2 y y .35
Birth weight, kg 2.6 0.8–8.6 .12
Gestational age, wk 0.8 0.6–1.1 .15
Age at operation, wk 1.0 0.8–1.1 .76
PGE at time of operation 0.6 0.2–2.1 .53
Preoperative inotropes 1.2 0.3–4.9 1.00
Single coronary artery 1.1 0.1–9.6 1.0
Steroids on CPB 0.2 0.1–0.7 .01
Phenoxybenzamine 2.5 0.3–21.0 .35
CPB time, min 1.0 0.9–1.1 .66
Aortic crossclamp time, min 1.0 0.9–1.0 .99
Circulatory arrest time, min* 1.0 0.9–1.1 .99
Hypoglycemia (any serum glucose value ,80 mg/dL)
Group 1 3.7 1.4–9.9 .008
Group 2 0.7 0.2–2.6 .75
Birth weight, kg 2.2 0.9–5.2 .06
Gestational age, wk 1.2 0.9–1.6 .23
Age at operation, wk 1.0 0.9–1.1 .41
PGE at time of operation 0.9 0.4–2.2 .80
Preoperative inotropes 0.8 0.3–2.4 .75
Single coronary artery 0.3 0.1–2.6 .43
Use of steroids on CPB 0.6 0.2–1.6 .27
Use of phenoxybenzamine 1.0 0.3–3.2 .98
CPB time, min 0.9 0.9–1.1 .49
Aortic crossclamp time, min 1.0 0.9–1.0 .17
Circulatory arrest time, min* 1.0 0.9–1.0 .97
CI, Confidence interval; PGE, prostaglandin E; CPB, cardiopulmonary
bypass. *Only for patients who had circulatory arrest. yNo patients had
renal insufficiency.744 The Journal of Thoracic and Cardiovascular Surgery c Apis not clear that this population would benefit in any way
from insulin therapy to keep SGVs within a tight range,
and conversely, there would be the real risk of inducing harm.
Conclusions
In contrast to adult critically ill patients, hyperglycemia does
not appear to be detrimental in postoperative infants with
congenital heart disease. Patients who spent the majority of
the first postoperative day with SGVs between 80 and 110
mg/dL were more likely to have periods of hypoglycemia
and AEs. Further investigation is warranted to define the op-
timal glucose level in this patient population, and following
the adult guidelines for glucose control is not warranted at
this time.
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